肺動脈高壓（PAH）為一種少見的慢性疾病，其危害性大、致死率高，多發(fā)于老年人和婦女。隨著我國步入老齡化社會，對PAH的防治越發(fā)重視。綜述了包括CCBs、PDE-5抑制劑、ERAs和PGI2類常規(guī)靶點和鳥苷酸環(huán)化酶激動劑，5-羥色胺，Bcr-Abl蛋白絡(luò)氨酸激酶抑制劑，Rho-激酶抑制劑，內(nèi)皮祖細(xì)胞和基因等治療該疾病的新型作用靶點在內(nèi)的最新靶點與藥物的研究進(jìn)展，以及新一代藥物的發(fā)展方向。

Pulmonary arterial hypertension (PAH) is a rare chronic disease with severe harm and a high mortality, and happens mainly in the elderly and women. Currently, as China is entering the aging society, more and more researches put the emphasis on the treatments of PAH. In this paper, it reviews the advanced development about new targets and drugs for treating this disease, such as calcium channel blockers (CCBs), phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonist (ERAs), and prostacyclin (PGI2), and new target consisting of guanylyl cyclase agonist, serotonin, Bcr-Abl protein tyrosine kinase inhibitors, Rho-kinase inhibitors, endothelial progenitors, and genes. In addition, it also introduces the direction of the new generation of drugs in the future.